240 related articles for article (PubMed ID: 12769771)
1. Death receptor signaling in cancer therapy.
Fulda S; Debatin KM
Curr Med Chem Anticancer Agents; 2003 Jul; 3(4):253-62. PubMed ID: 12769771
[TBL] [Abstract][Full Text] [Related]
2. Death receptors in chemotherapy and cancer.
Debatin KM; Krammer PH
Oncogene; 2004 Apr; 23(16):2950-66. PubMed ID: 15077156
[TBL] [Abstract][Full Text] [Related]
3. Signaling through death receptors in cancer therapy.
Fulda S; Debatin KM
Curr Opin Pharmacol; 2004 Aug; 4(4):327-32. PubMed ID: 15251124
[TBL] [Abstract][Full Text] [Related]
4. Targeting apoptosis pathways in cancer therapy.
Fulda S; Debatin KM
Curr Cancer Drug Targets; 2004 Nov; 4(7):569-76. PubMed ID: 15578914
[TBL] [Abstract][Full Text] [Related]
5. Modulation of TRAIL signaling for cancer therapy.
Fulda S; Debatin KM
Vitam Horm; 2004; 67():275-90. PubMed ID: 15110182
[TBL] [Abstract][Full Text] [Related]
6. Exploiting death receptor signaling pathways for tumor therapy.
Fulda S; Debatin KM
Biochim Biophys Acta; 2004 Dec; 1705(1):27-41. PubMed ID: 15585171
[TBL] [Abstract][Full Text] [Related]
7. Apoptosis signaling in tumor therapy.
Fulda S; Debatin KM
Ann N Y Acad Sci; 2004 Dec; 1028():150-6. PubMed ID: 15650241
[TBL] [Abstract][Full Text] [Related]
8. Apoptosis pathways in neuroblastoma therapy.
Fulda S; Debatin KM
Cancer Lett; 2003 Jul; 197(1-2):131-5. PubMed ID: 12880972
[TBL] [Abstract][Full Text] [Related]
9. Modulation of apoptosis signaling for cancer therapy.
Fulda S; Debatin KM
Arch Immunol Ther Exp (Warsz); 2006; 54(3):173-5. PubMed ID: 16652217
[TBL] [Abstract][Full Text] [Related]
10. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy.
Fulda S; Debatin KM
Oncogene; 2006 Aug; 25(34):4798-811. PubMed ID: 16892092
[TBL] [Abstract][Full Text] [Related]
11. TRAIL receptor signalling and modulation: Are we on the right TRAIL?
Mahalingam D; Szegezdi E; Keane M; de Jong S; Samali A
Cancer Treat Rev; 2009 May; 35(3):280-8. PubMed ID: 19117685
[TBL] [Abstract][Full Text] [Related]
12. Apoptotic pathways in tumor progression and therapy.
Melet A; Song K; Bucur O; Jagani Z; Grassian AR; Khosravi-Far R
Adv Exp Med Biol; 2008; 615():47-79. PubMed ID: 18437891
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic targeting of apoptotic pathways in cancer.
Meiler J; Schuler M
Curr Drug Targets; 2006 Oct; 7(10):1361-9. PubMed ID: 17073598
[TBL] [Abstract][Full Text] [Related]
14. Current status of the molecular mechanisms of anticancer drug-induced apoptosis. The contribution of molecular-level analysis to cancer chemotherapy.
Kim R; Tanabe K; Uchida Y; Emi M; Inoue H; Toge T
Cancer Chemother Pharmacol; 2002 Nov; 50(5):343-52. PubMed ID: 12439591
[TBL] [Abstract][Full Text] [Related]
15. Apoptosis in tumorigenesis and cancer therapy.
McGill G; Fisher DE
Front Biosci; 1997 Jul; 2():d353-79. PubMed ID: 9230063
[TBL] [Abstract][Full Text] [Related]
16. [Current concepts on apoptotic signalling pathways: new targets for anticancer strategies].
Ségal-Bendirdjian E; Hillion J; Belmokhtar CA
Bull Cancer; 2003 Jan; 90(1):9-17. PubMed ID: 12609799
[TBL] [Abstract][Full Text] [Related]
17. Control of apoptosis signaling by Apo2 ligand.
Marsters SA; Pitti RA; Sheridan JP; Ashkenazi A
Recent Prog Horm Res; 1999; 54():225-34. PubMed ID: 10548878
[TBL] [Abstract][Full Text] [Related]
18. Death receptors: targets for cancer therapy.
Mahmood Z; Shukla Y
Exp Cell Res; 2010 Apr; 316(6):887-99. PubMed ID: 20026107
[TBL] [Abstract][Full Text] [Related]
19. Targeting death receptors in bladder, prostate and renal cancer.
O'Kane HF; Watson CJ; Johnston SR; Petak I; Watson RW; Williamson KE
J Urol; 2006 Feb; 175(2):432-8. PubMed ID: 16406966
[TBL] [Abstract][Full Text] [Related]
20. Disruption of cell death signaling in cancer: impact on disease prognosis and response to therapy.
Güner D; Belka C; Daniel PT
Curr Med Chem Anticancer Agents; 2003 Sep; 3(5):319-26. PubMed ID: 12871077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
